01—Abstract
Summary
Summary of the 8-K filed July 31, 2026. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. has filed an 8-K report on July 31, 2026, to announce its financial results for the second quarter ended June 30, 2026.
The primary purpose of this filing is to furnish a press release containing these results, which is incorporated by reference. Investors should note that this information is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act, meaning it does not carry the same liabilities. However, it provides timely insights into Moderna's recent financial performance and operational status for the period.
While the specific financial figures are detailed in the furnished press release (Exhibit 99.1), the filing itself serves as the official notification of their disclosure. Investors and analysts will need to refer to the press release for details on revenue, earnings, product sales (particularly related to its mRNA platform and any approved vaccines/therapeutics), research and development expenditures, and forward-looking guidance. This report is crucial for assessing the company's trajectory and its ability to execute on its pipeline and commercial strategies.
02—Key points
Key Highlights
- Moderna, Inc. announced Q2 2026 financial results on July 31, 2026, via an 8-K filing.
- The filing incorporates by reference a press release (Exhibit 99.1) containing detailed financial results.
- Information is furnished, not 'filed' under Section 18 of the Exchange Act, with implications for liability.
- Investors should consult the press release for specific Q2 2026 financial performance data.
- Key metrics likely include revenue, earnings per share, and updates on product sales and R&D.
- The report provides a snapshot of Moderna's financial health and operational progress for the second quarter.
03—Questions
Frequently Asked Questions
What are the key financial results for Moderna in Q2 2026?
The specific financial results for the second quarter ended June 30, 2026, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing. Investors should refer to that document for figures on revenue, net income, earnings per share, and other relevant financial metrics.
Does this 8-K filing contain forward-looking guidance from Moderna?
The provided 8-K filing itself does not detail forward-looking guidance. Such information is typically found within the furnished press release (Exhibit 99.1). Investors are advised to review the press release for any updated financial forecasts or strategic outlooks.
What is the significance of the information being 'furnished' versus 'filed'?
When information is 'furnished' under an 8-K, it means the company is providing it to the SEC for public dissemination but is not subject to the same liabilities under Section 18 of the Securities Exchange Act of 1934 as if it were 'filed.' While still important for investors, it's a technical distinction regarding legal accountability for the disclosed information.
Where can I find more detailed information about Moderna's Q2 2026 performance?
The most comprehensive details regarding Moderna's Q2 2026 financial results and operational updates are available in the press release issued by the company on July 31, 2026, which is attached as Exhibit 99.1 to this Form 8-K filing.
04—Continue